Eli Lilly and Co.’s share price reached 1,316.30 euros on the Lang & Schwarz platform, marking a 0.93 percent increase above its Xetra closing price, following new clinical trial data presented at the ObesityWeek 2026 conference in Washington.
The real-time valuation update on Monday, November 16, 2026, follows a Friday, November 13 closing price of 1,304.20 euros on Xetra, as reported by AD HOC NEWS editor-in-chief Rafael Müller. The upward movement coincides with pharmaceutical pipeline updates released by the company on November 14, detailing advanced trial outcomes for several metabolic therapies.
- Extended Pediatric Data: Long-term evaluations in adolescent populations show notable reductions in Body Mass Index over extended treatment windows.
The presentations in Washington, DC, which run through Tuesday, November 17, 2026, highlight expanded clinical metrics for EloraTZP, Retatrutide, Zepbound, and Foundayo. In a phase-2 clinical trial evaluating adults diagnosed with overweight, obesity, and type-2 diabetes, the combination therapy of Eloralintide and Tirzepatide known as EloraTZP produced a mean weight loss of up to 23.3 percent over a 48-week duration.
Alongside anthropometric changes, the data show that patient HbA1c levels—a standard laboratory marker reflecting average blood glucose over a three-month period—decreased by an average of up to 2.9 percentage points.
Retatrutide, another investigational molecule in Eli Lilly's pipeline, demonstrated clinical impact beyond simple weight reduction by addressing obesity-related comorbidities.
Meanwhile, evaluation of the already-marketed agent Zepbound demonstrated a mean Body Mass Index reduction of 21.4 percent among adolescent participants over a 72-week evaluation period. Both Retatrutide and Eloralintide remain in active clinical development phases as researchers continue to gather longitudinal safety and efficacy profiles.
| Therapeutic Candidate | Trial Phase / Duration | Primary Clinical Endpoint |
|---|---|---|
| EloraTZP (Eloralintide + Tirzepatide) | Phase 2 / 48 Weeks | Up to 23.3% weight loss; HbA1c reduced by up to 2.9 points |
| Zepbound | Adolescent Study / 72 Weeks | Mean BMI reduction of 21.4% |
| Retatrutide | Clinical Development | Reduction in sleep apnea events and knee osteoarthritis pain |
- Eli Lilly and Company. Corporate Communications and Pipeline Disclosures. November 14, 2026.
- AD HOC NEWS. Editorial reporting by Rafael Müller. Published November 16, 2026.